We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Tolerability and Efficacy of LCZ696 in Japanese Hypertensive Patients With Renal Dysfunction

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01593787
First Posted: May 8, 2012
Last Update Posted: August 13, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
  Purpose
This study assessed the safety, tolerability, and efficacy of LCZ696 in hypertensive patients with renal dysfunction.

Condition Intervention Phase
Hypertension With Renal Dysfunction Drug: LCZ696 Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multi-center, Open Label Study for Evaluation of the Safety, Tolerability and Efficacy of 8-week Treatment With LCZ696 in Japanese Hypertensive Patients With Renal Dysfunction

Further study details as provided by Novartis ( Novartis Pharmaceuticals ):

Primary Outcome Measures:
  • Percentage of Participants With Reported Adverse Events (Total Adverse Events, Serious Adverse Events and Death) [ Time Frame: 8 weeks ]
    Percentage of patients with total adverse events, serious adverse events and death were reported.


Secondary Outcome Measures:
  • Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) at Week 8 [ Time Frame: baseline, 8 weeks ]
    Sitting BP measurements were performed at screening through the end of study at every visit. Four separate sitting BP were obtained with a full two-minute interval between measurements.

  • Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) at Week 8 [ Time Frame: baseline, 8 weeks ]
  • Percentage of Participants Achieving a Successful BP Control at Week 8 [ Time Frame: 8 weeks ]
    A successful BP control was defined as msSBP <130 mmHg and msDBP <80 mmHg

  • Percentage of Participants Achieving SBP Control at Week 8 [ Time Frame: 8 weeks ]
    SBP control was defined as msSBP <130 mmHg.

  • Percentage of Participants Achieving DBP Control at Week 8 [ Time Frame: 8 weeks ]
    DBP control was defined as msDBP <80 mmHg.

  • Percentage of Participants Achieving a Successful Response Rate in msSBP at Week 8 [ Time Frame: 8 weeks ]
    Successful response rate was defined as msSBP <130 mmHg or a reduction of ≥20 mmHg from baseline

  • Percentage of Participants Achieving a Successful Response Rate in msDBP at Week 8 [ Time Frame: 8 weeks ]
    Successful response rate was defined as msDBP <80 mmHg or a reduction of ≥10 mmHg from baseline.


Enrollment: 32
Study Start Date: May 2012
Study Completion Date: March 2013
Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: LCZ696 100 mg
All participants were started on LCZ696 100 mg once daily on day 1.
Drug: LCZ696
100 mg, 200 mg, 400 mg tablets.
Experimental: LCZ696 200 mg
All participants were started on LCZ696 100 mg once daily on day 1. For participants who did not achieve msDBP <80 mmHg and msSBP <130 mmHg at or after week 2 and had no signs of safety concerns at specified visits during the treatment epoch, the LCZ696 dose was increased to LCZ696 200 mg.
Drug: LCZ696
100 mg, 200 mg, 400 mg tablets.
Experimental: LCZ696 400 mg
All participants were started on LCZ696 100 mg once daily on day 1. For participants who received LCZ696 200 mg and did not achieve msDBP <80 mmHg and msSBP <130 mmHg at or after week 4 and had no signs of safety concerns at specified visits during the treatment epoch, the LCZ696 dose was increased to LCZ696 400 mg.
Drug: LCZ696
100 mg, 200 mg, 400 mg tablets.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Renal findings: Hypertensive patients with renal dysfunction and stable renal condition at least 4 weeks before screening visit.
  • Satisfy office msSBP ≥140 mmHg and <180 mmHg at baseline.

Exclusion Criteria:

  • Patients show msDBP ≥110 mmHg and/or msSBP ≥180 mmHg.
  • History of angioedema, drug-related or otherwise, as reported by the patient.
  • Any other following renal disorder:
  • Patients show eGFR < 15mL/min/1.73m^2
  • Patients on dialysis
  • Patients who previously entered a LCZ696 study and had been randomized or enrolled into the active drug treatment epoch.

Other protocol-defined inclusion/exclusion criteria may apply.

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01593787


Locations
Japan
Novartis Investigative Site
Sapporo-city, Hokkaido, Japan, 063-0842
Novartis Investigative Site
Sapporo, Hokkaido, Japan, 003-0026
Novartis Investigative Site
Sapporo, Hokkaido, Japan, 003-0825
Novartis Investigative Site
Aira-city, Kagoshima, Japan, 899-5431
Novartis Investigative Site
Kawasaki-city, Kanagawa, Japan, 210-0852
Novartis Investigative Site
Yokohama-city, Kanagawa, Japan, 231-0023
Novartis Investigative Site
Sendai-city, Miyagi, Japan, 980-8574
Novartis Investigative Site
Kurashiki, Okayama, Japan, 701-0192
Novartis Investigative Site
Fujimino, Saitama, Japan, 356-0053
Novartis Investigative Site
Hachioji-city, Tokyo, Japan, 192-0918
Novartis Investigative Site
Minato-ku, Tokyo, Japan, 108-0075
Novartis Investigative Site
Shinagawa-ku, Tokyo, Japan, 141-0032
Novartis Investigative Site
Osaka, Japan, 536-0008
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

Publications:
Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT01593787     History of Changes
Other Study ID Numbers: CLCZ696A1304
First Submitted: April 30, 2012
First Posted: May 8, 2012
Results First Submitted: July 8, 2015
Results First Posted: August 13, 2015
Last Update Posted: August 13, 2015
Last Verified: August 2015

Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Hypertension
Renal dysfunction
LCZ696

Additional relevant MeSH terms:
Hypertension
Renal Insufficiency
Vascular Diseases
Cardiovascular Diseases
Kidney Diseases
Urologic Diseases
LCZ 696
Angiotensin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action